Risedronic acid

Drug Profile

Risedronic acid

Alternative Names: Acrel; Actonel; Actonel Combi; Actonel plus Calcium; Actonel with Calcium; Atelvia; Benet; NE-58095; NE-58095NF; Optinate; Optinate Septimum; Ribastamin; Risedronate; Risedronate sodium; Sodium risedronate hydrate; WC3051

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Ajinomoto; Allergan; Procter & Gamble; Sanofi; Takeda
  • Class Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteitis deformans
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Corticosteroid-induced osteoporosis; Male osteoporosis; Osteitis deformans; Osteoporosis; Postmenopausal osteoporosis
  • Discontinued Osteogenesis imperfecta

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 23 Mar 2015 Discontinued - Phase-III for Osteogenesis imperfecta (In children) in USA, Australia, Belgium, Chile, Czech Republic, Finland, Germany, Hungary, Italy, Poland, South Africa, Spain and the UK (PO, tablet)
  • 11 Jun 2014 Generic equivalent available in USA for the treatment and prevention of Postmenopausal osteoporosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top